

POSTER PRESENTATION

Open Access

Application of Pearson correlation coefficient (PCC) and Kolmogorov-Smirnov distance (KSD) metrics to identify disease-specific biomarker genes

Hung-Chung Huang^{1,2}, Siyuan Zheng^{1,2,3}, Zhongming Zhao^{1,2,3*}

From UT-ORNL-KBRIN Bioinformatics Summit 2010
Cadiz, KY, USA. 19-21 March 2010

Background

DNA microarrays have been widely applied in cancer research for better diagnosis and prediction of the disease states. Traditionally, most microarray studies aim to identify differentially expressed genes (DEGs) by comparing the average gene expression levels between two groups (e.g., the treated vs. control or disease vs. non-disease) based on statistical analysis such as t-test and Significance Analysis of Microarrays (SAM) [1,2].

Materials and methods

In this study, we defined the gene expression profile (GEP) of a gene as the distribution of the log₂ values of its normalized expression signal intensities across the samples in the similarly studied microarrays. We hypothesized that the biomarker genes that distinguish disease samples from normal samples might form distinct GEPs between comparison groups. We applied Pearson Correlation Coefficient (PCC) and Kolmogorov-Smirnov Distance (KSD) metrics to identify disease-specific biomarkers by comparing GEPs between normal and disease states and then applied this technology to disease (e.g., cancer) related studies in order to discover some disease genes as biomarker candidates. These biomarkers' gene profiles in normal and disease samples might be used to diagnose or monitor patient's disease state via regular gene expression analysis.

Table 1 Top 10 gene pairs for top prediction accuracies on PCA diagnosis.

Down gene	Up gene	True positive	True negative	Accuracy
PCC sort*				
ACTA1	CRISP3	67/90	73/81	140/171
TGFB3	BICD1	72/90	68/81	140/171
ACTA1	HPN	76/90	63/81	139/171
MYL9	CRISP3	64/90	75/81	139/171
AL044599	BICD1	75/90	64/81	139/171
DMN	CRISP3	65/90	73/81	138/171
GJA1	CRISP3	70/90	68/81	138/171
AL036744	CRISP3	65/90	73/81	138/171
DMN	BICD1	69/90	69/81	138/171
ADH5	BICD1	71/90	67/81	138/171
KSD sort**				
GSTP1	CRISP3	68/90	72/81	140/171
AOC3	CRISP3	69/90	70/81	139/171
GSTP1	UBE2C	66/90	73/81	139/171
HLA-E	RGS10	71/90	68/81	139/171
GSTP1	HPN	70/90	68/81	138/171
DMN	CRISP3	65/90	73/81	138/171
GJA1	CRISP3	70/90	68/81	138/171
HLA-E	UBE2C	61/90	77/81	138/171
DMN	BICD1	69/90	69/81	138/171
PALLD	BICD1	66/90	72/81	138/171

*PCC sort: significant genes were separated into down- and up-regulated groups, then the top 20 genes (sorted by Pearson Correlation Coefficient in the cancer vs. normal GEPs for each gene) in each group were selected to generate pair-wise gene-pairs for the PCA prediction.

**KSD sort: significant genes were separated into down- and up-regulated groups, then the top 20 genes (sorted by Kolmogorov-Smirnov Distance in the cancer vs. normal GEPs for each gene) in each group were selected to generate pair-wise gene-pairs for the PCA prediction.

* Correspondence: zhongming.zhao@vanderbilt.edu

¹Functional Genomics Shared Resource, Vanderbilt University Medical Center, Nashville, TN 37232, USA

Results and conclusion

We applied the PCC and KSD metrics to three prostate cancer related microarray datasets. They were generated from the same study and were available in the GEO database (a total of 81 normal samples and 90 prostate cancer samples) [3]. Using the cutoff values $KSD > 0.4$ and $PCC < 0.7$, we found 230 biomarker candidate genes. Our Gene Ontology (GO) analysis found that the top ranked biomarker candidate genes for prostate cancer were highly enriched in molecular functions such as “cytoskeletal protein binding” category. We used the top two ranked genes (*ACTA1*, encoding an actin subunit, and *HPN*, encoding hepsin) to demonstrate that prostate cancer might be diagnosed and monitored by marker genes. Furthermore, we picked top 20 significantly up-regulated and top 20 down-regulated genes based on PCC and KSD sorting. We found gene pairs comprising one up-regulated and another down-regulated had always best prediction performance (Table 1). Our study provided a promising tool to identify the potential biomarker genes for disease diagnosis and prognosis.

Author details

¹Functional Genomics Shared Resource, Vanderbilt University Medical Center, Nashville, TN 37232, USA. ²Bioinformatics Resource Center, Vanderbilt University Medical Center, Nashville, TN 37203, USA. ³Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

Published: 23 July 2010

References

1. Jafari P, Azuaje F: An assessment of recently published gene expression data analyses: reporting experimental design and statistical factors. *BMC Med Inform Decis Mak* 2006, **6**:27.
2. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci USA* 2001, **98**:5116-5121.
3. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA: Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. *BMC Cancer* 2007, **7**:64.

doi:10.1186/1471-2105-11-S4-P23

Cite this article as: Huang *et al.*: Application of Pearson correlation coefficient (PCC) and Kolmogorov-Smirnov distance (KSD) metrics to identify disease-specific biomarker genes. *BMC Bioinformatics* 2010 **11** (Suppl 4):P23.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

